Louis Frederic Diehl, MD

Professor of Medicine
Member of the Duke Cancer Institute
Campus mail 2400 Pratt St Suite 5000, DUMC Box 3961, Durham, NC 27710
Phone (919) 668-1000
Email address louis.diehl@duke.edu

Research interests include Hodgkin disease, non-Hodgkin lymphomas, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myelodysplasia.

In Their Words

Education and Training

  • Fellow in Hematology-Oncology, Medicine, Walter Reed Army Medical Center, 1978 - 1981
  • Medical Resident, Medicine, Walter Reed Army Medical Center, 1975 - 1978
  • M.D., Georgetown University, 1975

Publications

Berdeja, Jesús G., Allan Hess, David M. Lucas, Paul O’Donnell, Richard F. Ambinder, Louis F. Diehl, Denise Carter-Brookins, Susan Newton, and Ian W. Flinn. “Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab.” Clin Cancer Res 13, no. 8 (April 15, 2007): 2392–99. https://doi.org/10.1158/1078-0432.CCR-06-1860.

PMID
17438098
Full Text

Willis, Carl R., Amy Goodrich, Kathy Park, Jamie K. Waselenko, Margaret Lucas, Amy Reese, Louis F. Diehl, Michael R. Grever, John C. Byrd, and Ian W. Flinn. “A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin's lymphoma.” Ann Hematol 85, no. 5 (May 2006): 301–7. https://doi.org/10.1007/s00277-005-0025-9.

PMID
16518606
Full Text

Kasamon, Yvette L., Ian W. Flinn, Michael R. Grever, Louis F. Diehl, Elizabeth Garrett-Mayer, Steven N. Goodman, Margaret S. Lucas, and John C. Byrd. “Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia.” Clin Cancer Res 11, no. 23 (December 1, 2005): 8413–17. https://doi.org/10.1158/1078-0432.CCR-05-1612.

PMID
16322303
Full Text

Matsui, William, B Douglas Smith, Milada Vala, Nikeshia Beal, Carol Ann Huff, Louis F. Diehl, and Richard J. Jones. “Requirement for myeloid growth factors in the differentiation of acute promyelocytic leukaemia.” Br J Haematol 128, no. 6 (March 2005): 853–62. https://doi.org/10.1111/j.1365-2141.2005.05395.x.

PMID
15755292
Full Text

Kasamon, Yvette L., Richard J. Jones, Louis F. Diehl, Hassan Nayer, Michael J. Borowitz, Elizabeth Garrett-Mayer, Richard F. Ambinder, Ross A. Abrams, Zhe Zhang, and Ian W. Flinn. “Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma.” Biol Blood Marrow Transplant 11, no. 1 (January 2005): 39–46. https://doi.org/10.1016/j.bbmt.2004.09.007.

PMID
15625543
Full Text

Huff, Carol Ann, Ephraim J. Fuchs, Stephen J. Noga, Paul V. O’Donnell, Richard F. Ambinder, Louis Diehl, Ivan Borrello, et al. “Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells.” Biol Blood Marrow Transplant 9, no. 5 (May 2003): 312–19. https://doi.org/10.1016/s1083-8791(03)00075-2.

PMID
12766881
Full Text

Willard, R. J., G. W. Turiansky, G. P. Genest, B. J. Davis, and L. F. Diehl. “Leukemia cutis in a patient with chronic neutrophilic leukemia.” J Am Acad Dermatol 44, no. 2 Suppl (February 2001): 365–69. https://doi.org/10.1067/mjd.2001.103996.

PMID
11174417
Full Text

Flinn, I. W., J. C. Byrd, C. Morrison, J. Jamison, L. F. Diehl, T. Murphy, S. Piantadosi, et al. “Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies.” Blood 96, no. 1 (July 1, 2000): 71–75.

PMID
10891432
Scholars@Duke

Flinn, I. W., S. N. Goodman, L. Post, J. Jamison, C. B. Miller, S. Gore, L. Diehl, C. Willis, R. F. Ambinder, and J. C. Byr. “A dose-finding study of liposomal daunorubicin with CVP (COP-X) in advanced NHL.” Ann Oncol 11, no. 6 (June 2000): 691–95. https://doi.org/10.1023/a:1008361914894.

PMID
10942057
Full Text

LeBrun, C. J., L. F. Diehl, K. C. Abbott, P. G. Welch, and C. M. Yuan. “Life expectancy benefits of cancer screening in the end-stage renal disease population.” Am J Kidney Dis 35, no. 2 (February 2000): 237–43. https://doi.org/10.1016/s0272-6386(00)70332-5.

PMID
10676722
Full Text

Pages